Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

SML1027

Sigma-Aldrich

Imatinib mesylate

≥98% (HPLC), powder, tyrosine kinase inhibitor

Sinônimo(s):

4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate, 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide mesylate, CGP 57148, Genfatinib, Glivec, Imatinib methanesulfonate, STI-571

Faça loginpara ver os preços organizacionais e de contrato

Selecione um tamanho

10 MG
R$ 212,00
100 MG
R$ 725,00

R$ 212,00


Disponível para enviar em14 de abril de 2025Detalhes


Solicite uma grande encomenda

Selecione um tamanho

Alterar visualização
10 MG
R$ 212,00
100 MG
R$ 725,00

About This Item

Fórmula empírica (Notação de Hill):
C29H31N7O · CH4O3S
Número CAS:
Peso molecular:
589.71
Código UNSPSC:
12352200
NACRES:
NA.77

R$ 212,00


Disponível para enviar em14 de abril de 2025Detalhes


Solicite uma grande encomenda

Nome do produto

Imatinib mesylate, ≥98% (HPLC)

Ensaio

≥98% (HPLC)

Formulário

powder

condição de armazenamento

desiccated

cor

white to beige

solubilidade

H2O: 10 mg/mL, clear

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

[S](=O)(=O)([O-])C.[N+H]1(CCN(CC1)Cc2ccc(cc2)C(=O)Nc3cc(c(cc3)C)Nc4nc(ccn4)c5cnccc5)C

InChI

1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)

chave InChI

YLMAHDNUQAMNNX-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Aplicação

Imatinib mesylate (IM) has been used:
  • in sulforhodamine B cell viability assay to study its effect on CD34+ or CD38- and CD34+ or CD38+ cells[1]
  • as an abelson1 (ABL1) kinase inhibitor[2]
  • in circular dichroism analysis to study the effect of IM binding on the secondary structure of the human transferrins[3]

Ações bioquímicas/fisiológicas

Imatinib mesylate is a tyrosine kinase inhibitor with antineoplastic activity.
Imatinib mesylate is a tyrosine kinase inhibitor with antineoplastic activity. Imatinib is a potent inhibitor of the Bcr-Abl kinase encoded by the bcr-abl oncogene as well as receptor tyrosine kinases encoded by c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Imatinib mesylate inhibition of Bcr-Abl tyrosine kinase created by the Philadelphia chromosome abnormality found in CML decreases proliferation and enhances apoptosis in leukemias CML and ALL. Inhibition of c-kit tyrosine activity inhibits mast-cell and cellular proliferation in those diseases overexpressing c-kit such as gastrointestinal stromal tumor (GIST).

Características e benefícios

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Outras notas

Imatinib has been expertly reviewed and recommended by the Chemical Probes Portal. For more information, please visit the Imatinib probe summary on the Chemical Probes Portal website.

Pictogramas

Health hazard

Palavra indicadora

Warning

Frases de perigo

Classificações de perigo

Repr. 2

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 8

1 of 8

Optogenetic reconstitution reveals that Dynein-Dynactin-NuMA clusters generate cortical spindle-pulling forces as a multi-arm ensemble.
Okumura M, et al.
bioRxiv, 277202-277202 (2018)
Wei Ye et al.
Oncotarget, 8(50), 87002-87015 (2016-07-28)
Available therapeutic options for advanced B cell precursor acute lymphoblastic leukemia (pre-B ALL) are limited. Many lead to neutropenia, leaving patients at risk of life-threatening infections and result in bad outcomes. New treatment options are needed to improve overall survival.
Interaction of imatinib mesylate with human serum transferrin: the comparative spectroscopic studies.
Sliwinska-Hill U, et al.
Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy, 173, 468-475 (2017)
Julien Solinc et al.
Journal of the American Heart Association, 11(7), e023021-e023021 (2022-03-30)
Background Platelet-derived growth factor is a major regulator of the vascular remodeling associated with pulmonary arterial hypertension. We previously showed that protein widely 1 (PW1+) vascular progenitor cells participate in early vessel neomuscularization during experimental pulmonary hypertension (PH) and we
Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway
Tu Y X, et al.
Oncotarget, 9(3), 3267-3267 (2018)

Artigos

Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica